Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?

作者：Goldblatt Mark; Huggins J Terrill; Doelken Peter; Gurung Puncho; Sahn Steven A^*

来源：American Journal of the Medical Sciences, 2009, 338(5): 414-417.

DOI：10.1097/maj.0b013e3181ae9227

• Dasatinib
• Pleural effusion
• Transudates
• Chylous effusions

Dasatanib, which has been approved for rescue therapy for patients with imatinib-resistant chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, is a novel, orally available multitargeted kinase inhibitor of BCR-ABL and SRC family kinases (Quintas-Cardama et at, J Clin Oncol 2007;25:3908-14). It binds to both active and inactive conformations of the ABL gene and is 325 times more potent than imatinib in inhibiting the growth of BCR/ABL cells in vitro (Morelock and Satin, Chest 1999;116:212-21; Huggins and Satin, Clin Chest Med 2004;25:141-53). Although dasatinib is a generally well-tolerated drug in the treatment of Philadelphia chromosome positive hematopoetic malignancies, pleural effusions have been frequently noted and have been reported in up to 35% of patients (Sahn SA. Drug-induced pleural disease. In: Camus P, Rosenow E, editors. Drug-induced iatrogenic lung disease. London: Hodder Arnold; 2009). Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis: therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.

• 出版日期2009-11